{"id":"dtec-dtt","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":{"chemblId":"CHEMBL47903","moleculeType":"Small molecule","molecularWeight":"154.26"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This is a neoadjuvant or adjuvant chemotherapy schedule designed to deliver multiple cytotoxic agents in a sequential manner to maximize tumor cell kill while managing tolerability. The regimen alternates between different drug combinations to potentially reduce resistance and optimize therapeutic benefit in breast cancer patients.","oneSentence":"dtEC→dtT is a sequential chemotherapy regimen combining docetaxel and epirubicin followed by docetaxel and paclitaxel for breast cancer treatment.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:10:09.653Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (neoadjuvant or adjuvant treatment)"}]},"trialDetails":[{"nctId":"NCT00798070","phase":"PHASE3","title":"Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2007-02","conditions":"Breast Cancer","enrollment":2017}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epirubicin","Cyclophosphamide","Taxotere"],"phase":"phase_3","status":"active","brandName":"dtEC→dtT","genericName":"dtEC→dtT","companyName":"Karolinska University Hospital","companyId":"karolinska-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"dtEC→dtT is a sequential chemotherapy regimen combining docetaxel and epirubicin followed by docetaxel and paclitaxel for breast cancer treatment. Used for Breast cancer (neoadjuvant or adjuvant treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}